Shares of Moderna Inc. MRNA were up about 1.0% in premarket trading on Monday after the company reiterated that it expects to have $5.0 billion in sales of its COVID-19 vaccine in 2023. Moderna also said its vaccine generated $18.4 billion in sales in 2022, and the company plans to boost spending on research and development to $4.5 billion this year, up from $3.3 billion in 2022. Moderna provided the update in advance of the company’s presentation at the annual J.P. Morgan Healthcare Conference in San Francisco. Moderna’s stock is down 15.6% over the past year, while the broader S&P 500 SPX has declined 17.0%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.